GSA Capital Partners LLP reduced its stake in shares of Boston Scientific Corp. (NYSE:BSX) by 73.4% during the second quarter, Holdings Channel reports. The firm owned 20,692 shares of the company’s stock after selling 57,053 shares during the period. GSA Capital Partners LLP’s holdings in Boston Scientific Corp. were worth $484,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new stake in Boston Scientific Corp. during the fourth quarter valued at $194,589,000. Wellington Management Group LLP increased its stake in Boston Scientific Corp. by 9.1% in the first quarter. Wellington Management Group LLP now owns 103,378,526 shares of the company’s stock valued at $1,944,549,000 after buying an additional 8,643,058 shares during the period. Columbus Circle Investors bought a new stake in Boston Scientific Corp. during the second quarter valued at $64,918,000. Emerald Acquisition Ltd. bought a new stake in Boston Scientific Corp. during the second quarter valued at $19,134,000. Finally, Strs Ohio increased its stake in Boston Scientific Corp. by 1,154.5% in the second quarter. Strs Ohio now owns 846,118 shares of the company’s stock valued at $19,773,000 after buying an additional 778,670 shares during the period. Hedge funds and other institutional investors own 92.27% of the company’s stock.

Shares of Boston Scientific Corp. (NYSE:BSX) traded down 0.51% on Friday, reaching $23.50. 13,251,776 shares of the company’s stock traded hands. The company has a 50 day moving average price of $24.02 and a 200 day moving average price of $21.85. The firm’s market capitalization is $31.98 billion. Boston Scientific Corp. has a 52 week low of $15.67 and a 52 week high of $24.79.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.27 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.27. The company earned $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. Boston Scientific Corp. had a negative net margin of 4.34% and a positive return on equity of 22.66%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same period last year, the business earned $0.22 EPS. On average, equities research analysts predict that Boston Scientific Corp. will post ($0.02) earnings per share for the current fiscal year.

BSX has been the subject of several research reports. Zacks Investment Research downgraded shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Guggenheim started coverage on shares of Boston Scientific Corp. in a research note on Wednesday, June 8th. They issued a “buy” rating and a $26.00 price target for the company. Citigroup Inc. boosted their price target on shares of Boston Scientific Corp. from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, August 3rd. Credit Suisse Group AG restated a “buy” rating on shares of Boston Scientific Corp. in a research note on Friday, July 29th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $26.00 price target on shares of Boston Scientific Corp. in a research note on Tuesday, June 21st. Six equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $25.03.

In other Boston Scientific Corp. news, CEO Michael F. Mahoney sold 44,400 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $24.44, for a total transaction of $1,085,136.00. Following the completion of the transaction, the chief executive officer now directly owns 1,388,177 shares of the company’s stock, valued at approximately $33,927,045.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael P. Phalen sold 35,000 shares of the firm’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $24.03, for a total transaction of $841,050.00. The disclosure for this sale can be found here. Company insiders own 1.31% of the company’s stock.

About Boston Scientific Corp.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

5 Day Chart for NYSE:BSX

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corp. (NYSE:BSX).

Receive News & Ratings for Boston Scientific Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.